UMB Financial plans to refile a $6.4 billion against Bristol-Myers Squibb by shareholders owning contingent value rights over ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

UMB Bank NA filed suit against Bristol-Myers in 2021, alleging that the company intentionally slow-rolled the approval ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...

Celgene paid $7.2 billion to acquire Receptos and its multiple sclerosis hopeful ozanimod in 2015 – but it has hit a major setback after the FDA refused to accept its dossier. The New Jersey ...

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...

Evotec and Celgene partnered up in October 2017 to work on degenerative diseases, including Alzheimer’s. They signed a five-year agreement whereby Evotec received an upfront payment of €43m ...

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations ...